S1PR1 and myeloid sarcoma: Notably, selective removal of the S1P receptor subtype S1P1 from astrocytes was found to reduce astrogliosis, disease severity, and FTY720 efficacy in EAE (experimental autoimmune encephalomyelitis), an animal model of MS [26], despite the maintenance of S1P1 in the immune system.